You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMivacurium
Accession NumberDB01226  (APRD01119)
TypeSmall Molecule
GroupsApproved
DescriptionMivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
Structure
Thumb
Synonyms
Mivacurium
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MivacronSolution2 mg/mLIntravenousAbb Vie Inc.2015-01-30Not applicableUs
MivacronLiquid2 mgIntravenousAbbvie Corporation1994-12-312012-11-03Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mivacurium chloride
106861-44-3
Thumb
  • InChI Key: WMSYWJSZGVOIJW-ONUALHDOSA-L
  • Monoisotopic Mass: 1098.4986607
  • Average Mass: 1100.18
DBSALT001359
Categories
UNII77D66S9Q93
CAS number133814-19-4
WeightAverage: 1029.2608
Monoisotopic: 1028.560955278
Chemical FormulaC58H80N2O14
InChI KeyILVYCEVXHALBSC-OTBYEXOQSA-N
InChI
InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1
IUPAC Name
(1R)-2-(3-{[(4E)-8-{3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium
SMILES
COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[[email protected]]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC
Pharmacology
IndicationFor inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Structured Indications Not Available
PharmacodynamicsMivacurium is a short-acting, nondepolarizing skeletal neuromuscular blocking agent which is hydrolyzed by plasma cholinesterase. Mivacurium results in a blockade of neuromuscular transmission by binding competitively with cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine. The neuromuscular block produced by mivacurium is readily antagonized by anticholinesterase agents. The deeper the level of neuromuscular block at reversal, the longer the time required for recovery of neuromuscular function and the greater the dose of anticholinesterase agent required. Because spontaneous recovery after mivacurium is rapid, routine reversal may not always result in a clinical benefit.
Mechanism of actionMivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.
TargetKindPharmacological actionActionsOrganismUniProt ID
Neuronal acetylcholine receptor subunit alpha-2Proteinyes
antagonist
HumanQ15822 details
Muscarinic acetylcholine receptor M2Proteinno
antagonist
partial agonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinno
antagonist
HumanP20309 details
CholinesteraseProteinunknownNot AvailableHumanP06276 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingThe protein binding of mivacurium has not been determined due to its rapid hydrolysis by plasma cholinesterase.
Metabolism

Extensive and rapid via enzymatic hydrolysis catalyzed by plasma cholinesterase. Biotransformation may be significantly slowed in patients with abnormal or decreased plasma cholinesterase activity, especially individuals with a homozygous atypical cholinesterase gene abnormality.

Route of eliminationNot Available
Half lifeThe mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.
ClearanceNot Available
ToxicityOverdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may decrease the neuromuscular blocking activities of Mivacurium.Experimental
16-BromoepiandrosteroneMivacurium may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneMivacurium may increase the adverse neuromuscular activities of 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneMivacurium may increase the adverse neuromuscular activities of 4-Androstenedione.Experimental, Illicit
5-androstenedioneMivacurium may increase the adverse neuromuscular activities of 5-androstenedione.Experimental, Illicit
AcetyldigitoxinMivacurium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AclarubicinAclarubicin may increase the respiratory depressant activities of Mivacurium.Investigational
AlclometasoneMivacurium may increase the adverse neuromuscular activities of Alclometasone.Approved
AldosteroneMivacurium may increase the adverse neuromuscular activities of Aldosterone.Experimental
AmbenoniumAmbenonium may decrease the neuromuscular blocking activities of Mivacurium.Approved
AmcinonideMivacurium may increase the adverse neuromuscular activities of Amcinonide.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Mivacurium.Approved, Vet Approved
AmlodipineAmlodipine may increase the neuromuscular blocking activities of Mivacurium.Approved
AmrinoneAmrinone may increase the neuromuscular blocking activities of Mivacurium.Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Mivacurium.Approved, Investigational
AnecortaveMivacurium may increase the adverse neuromuscular activities of Anecortave.Investigational
annamycinannamycin may increase the respiratory depressant activities of Mivacurium.Investigational
AnvirzelMivacurium may increase the arrhythmogenic activities of Anvirzel.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Mivacurium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Mivacurium.Approved
AzelnidipineAzelnidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
AzimilideAzimilide may increase the neuromuscular blocking activities of Mivacurium.Investigational
BarnidipineBarnidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
BeclomethasoneMivacurium may increase the adverse neuromuscular activities of Beclomethasone.Investigational
Beclomethasone dipropionateMivacurium may increase the adverse neuromuscular activities of Beclomethasone dipropionate.Approved, Investigational
BenidipineBenidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
BepridilBepridil may increase the neuromuscular blocking activities of Mivacurium.Approved, Withdrawn
BetamethasoneMivacurium may increase the adverse neuromuscular activities of Betamethasone.Approved, Vet Approved
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
Botulinum Toxin Type BMivacurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BudesonideMivacurium may increase the adverse neuromuscular activities of Budesonide.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Mivacurium.Approved
CaiCai may increase the neuromuscular blocking activities of Mivacurium.Investigational
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Mivacurium.Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
CiclesonideMivacurium may increase the adverse neuromuscular activities of Ciclesonide.Approved, Investigational
CilnidipineCilnidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
CinnarizineCinnarizine may increase the neuromuscular blocking activities of Mivacurium.Approved
ClevidipineClevidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
ClindamycinClindamycin may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
ClobetasolMivacurium may increase the adverse neuromuscular activities of Clobetasol.Investigational
Clobetasol propionateMivacurium may increase the adverse neuromuscular activities of Clobetasol propionate.Approved
ClocortoloneMivacurium may increase the adverse neuromuscular activities of Clocortolone.Approved
ColistimethateColistimethate may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
Cortisone acetateMivacurium may increase the adverse neuromuscular activities of Cortisone acetate.Approved
CoumaphosCoumaphos may decrease the neuromuscular blocking activities of Mivacurium.Vet Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational, Vet Approved
DarodipineDarodipine may increase the neuromuscular blocking activities of Mivacurium.Experimental
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Mivacurium.Approved
DecamethoniumDecamethonium may decrease the neuromuscular blocking activities of Mivacurium.Approved
dehydroepiandrosterone sulfateMivacurium may increase the adverse neuromuscular activities of dehydroepiandrosterone sulfate.Investigational
DemecariumDemecarium may decrease the neuromuscular blocking activities of Mivacurium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Mivacurium.Approved
DesfluraneDesflurane may increase the neuromuscular blocking activities of Mivacurium.Approved
DeslanosideMivacurium may increase the arrhythmogenic activities of Deslanoside.Approved
DesoximetasoneMivacurium may increase the adverse neuromuscular activities of Desoximetasone.Approved
Desoxycorticosterone acetateMivacurium may increase the adverse neuromuscular activities of Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateMivacurium may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneMivacurium may increase the adverse neuromuscular activities of Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateMivacurium may increase the adverse neuromuscular activities of Dexamethasone isonicotinate.Vet Approved
DichlorvosDichlorvos may decrease the neuromuscular blocking activities of Mivacurium.Vet Approved
DiflorasoneMivacurium may increase the adverse neuromuscular activities of Diflorasone.Approved
DifluocortoloneMivacurium may increase the adverse neuromuscular activities of Difluocortolone.Approved
DifluprednateMivacurium may increase the adverse neuromuscular activities of Difluprednate.Approved
DigitoxinMivacurium may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinMivacurium may increase the arrhythmogenic activities of Digoxin.Approved
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Mivacurium.Vet Approved
DiltiazemDiltiazem may increase the neuromuscular blocking activities of Mivacurium.Approved
DonepezilDonepezil may decrease the neuromuscular blocking activities of Mivacurium.Approved
DotarizineDotarizine may increase the neuromuscular blocking activities of Mivacurium.Investigational
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Mivacurium.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational, Vet Approved
EchothiophateEchothiophate may decrease the neuromuscular blocking activities of Mivacurium.Approved
EdrophoniumEdrophonium may decrease the neuromuscular blocking activities of Mivacurium.Approved
EfonidipineEfonidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
EnfluraneEnflurane may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
EperisoneEperisone may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
EpirubicinEpirubicin may increase the respiratory depressant activities of Mivacurium.Approved
EquileninMivacurium may increase the adverse neuromuscular activities of Equilenin.Experimental
EquilinMivacurium may increase the adverse neuromuscular activities of Equilin.Approved
EstroneMivacurium may increase the adverse neuromuscular activities of Estrone.Approved
Estrone sulfateMivacurium may increase the adverse neuromuscular activities of Estrone sulfate.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Mivacurium.Approved
FelodipineFelodipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
FendilineFendiline may increase the neuromuscular blocking activities of Mivacurium.Withdrawn
FenthionFenthion may decrease the neuromuscular blocking activities of Mivacurium.Vet Approved
fluasteroneMivacurium may increase the adverse neuromuscular activities of fluasterone.Investigational
FludrocortisoneMivacurium may increase the adverse neuromuscular activities of Fludrocortisone.Approved
FlumethasoneMivacurium may increase the adverse neuromuscular activities of Flumethasone.Approved, Vet Approved
FlunarizineFlunarizine may increase the neuromuscular blocking activities of Mivacurium.Approved
FlunisolideMivacurium may increase the adverse neuromuscular activities of Flunisolide.Approved, Investigational
Fluocinolone AcetonideMivacurium may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideMivacurium may increase the adverse neuromuscular activities of Fluocinonide.Approved, Investigational
FluocortoloneMivacurium may increase the adverse neuromuscular activities of Fluocortolone.Approved, Withdrawn
FluorometholoneMivacurium may increase the adverse neuromuscular activities of Fluorometholone.Approved
FluprednideneMivacurium may increase the adverse neuromuscular activities of Fluprednidene.Approved, Withdrawn
FluprednisoloneMivacurium may increase the adverse neuromuscular activities of Fluprednisolone.Approved
FlurandrenolideMivacurium may increase the adverse neuromuscular activities of Flurandrenolide.Approved
Fluticasone furoateMivacurium may increase the adverse neuromuscular activities of Fluticasone furoate.Approved
Fluticasone PropionateMivacurium may increase the adverse neuromuscular activities of Fluticasone Propionate.Approved
FormestaneMivacurium may increase the adverse neuromuscular activities of Formestane.Approved, Investigational, Withdrawn
FosphenytoinFosphenytoin may decrease the neuromuscular blocking activities of Mivacurium.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Mivacurium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
GabapentinGabapentin may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
GalantamineGalantamine may decrease the neuromuscular blocking activities of Mivacurium.Approved
Gallamine TriethiodideGallamine Triethiodide may decrease the neuromuscular blocking activities of Mivacurium.Approved
GallopamilGallopamil may increase the neuromuscular blocking activities of Mivacurium.Investigational
GeneticinGeneticin may increase the respiratory depressant activities of Mivacurium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Mivacurium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Mivacurium.Experimental
Ginkgo bilobaGinkgo biloba may decrease the neuromuscular blocking activities of Mivacurium.Approved, Nutraceutical
HalothaneHalothane may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
HE3286Mivacurium may increase the adverse neuromuscular activities of HE3286.Investigational
Huperzine AHuperzine A may decrease the neuromuscular blocking activities of Mivacurium.Investigational
HydrocortisoneMivacurium may increase the adverse neuromuscular activities of Hydrocortisone.Approved, Vet Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Mivacurium.Vet Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Mivacurium.Approved
INNO-206INNO-206 may increase the respiratory depressant activities of Mivacurium.Investigational
IsofluraneIsoflurane may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
IsoflurophateIsoflurophate may decrease the neuromuscular blocking activities of Mivacurium.Approved, Withdrawn
IsradipineIsradipine may increase the neuromuscular blocking activities of Mivacurium.Approved
IstaroximeMivacurium may increase the adverse neuromuscular activities of Istaroxime.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Mivacurium.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mivacurium.Approved
LacidipineLacidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
LamotrigineLamotrigine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
LercanidipineLercanidipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
LithiumLithium may increase the neuromuscular blocking activities of Mivacurium.Approved
Magnesium hydroxideMagnesium hydroxide may increase the neuromuscular blocking activities of Mivacurium.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Mivacurium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Mivacurium.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
MalathionMalathion may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
ManidipineManidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
ME-609Mivacurium may increase the adverse neuromuscular activities of ME-609.Investigational
MedrysoneMivacurium may increase the adverse neuromuscular activities of Medrysone.Approved
MefloquineMefloquine may decrease the neuromuscular blocking activities of Mivacurium.Approved
MelengestrolMivacurium may increase the adverse neuromuscular activities of Melengestrol.Vet Approved
MemantineMemantine may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
Methanesulfonyl FluorideMethanesulfonyl Fluoride may decrease the neuromuscular blocking activities of Mivacurium.Investigational
MethoxyfluraneMethoxyflurane may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
MethylprednisoloneMivacurium may increase the adverse neuromuscular activities of Methylprednisolone.Approved, Vet Approved
MetrizamideMetrizamide may increase the respiratory depressant activities of Mivacurium.Approved
MibefradilMibefradil may increase the neuromuscular blocking activities of Mivacurium.Withdrawn
MinaprineMinaprine may decrease the neuromuscular blocking activities of Mivacurium.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
MometasoneMivacurium may increase the adverse neuromuscular activities of Mometasone.Approved, Vet Approved
NaftopidilNaftopidil may increase the neuromuscular blocking activities of Mivacurium.Investigational
NCX 1022Mivacurium may increase the adverse neuromuscular activities of NCX 1022.Investigational
NeamineNeamine may increase the respiratory depressant activities of Mivacurium.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Mivacurium.Approved, Vet Approved
NeostigmineNeostigmine may decrease the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Mivacurium.Approved
NicardipineNicardipine may increase the neuromuscular blocking activities of Mivacurium.Approved
NifedipineNifedipine may increase the neuromuscular blocking activities of Mivacurium.Approved
NiguldipineNiguldipine may increase the neuromuscular blocking activities of Mivacurium.Experimental
NiludipineNiludipine may increase the neuromuscular blocking activities of Mivacurium.Experimental
NilvadipineNilvadipine may increase the neuromuscular blocking activities of Mivacurium.Approved
NimesulideNimesulide may increase the neuromuscular blocking activities of Mivacurium.Approved, Withdrawn
NimodipineNimodipine may increase the neuromuscular blocking activities of Mivacurium.Approved
NisoldipineNisoldipine may increase the neuromuscular blocking activities of Mivacurium.Approved
NitrendipineNitrendipine may increase the neuromuscular blocking activities of Mivacurium.Approved
Nitrous oxideNitrous oxide may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
Oleoyl estroneMivacurium may increase the adverse neuromuscular activities of Oleoyl estrone.Investigational
OuabainMivacurium may increase the arrhythmogenic activities of Ouabain.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
ParamethasoneMivacurium may increase the adverse neuromuscular activities of Paramethasone.Approved
ParomomycinParomomycin may increase the respiratory depressant activities of Mivacurium.Approved, Investigational
PerhexilinePerhexiline may increase the neuromuscular blocking activities of Mivacurium.Approved
PhenytoinPhenytoin may decrease the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
PhysostigminePhysostigmine may decrease the neuromuscular blocking activities of Mivacurium.Approved
PinaveriumPinaverium may increase the neuromuscular blocking activities of Mivacurium.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Mivacurium.Investigational
PiretanidePiretanide may decrease the neuromuscular blocking activities of Mivacurium.Experimental
PlicamycinPlicamycin may increase the respiratory depressant activities of Mivacurium.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
PrasteroneMivacurium may increase the adverse neuromuscular activities of Prasterone.Approved, Nutraceutical
PrednicarbateMivacurium may increase the adverse neuromuscular activities of Prednicarbate.Approved
PrednisoloneMivacurium may increase the adverse neuromuscular activities of Prednisolone.Approved, Vet Approved
PrednisoneMivacurium may increase the adverse neuromuscular activities of Prednisone.Approved, Vet Approved
PregabalinPregabalin may increase the neuromuscular blocking activities of Mivacurium.Approved, Illicit, Investigational
PregnenoloneMivacurium may increase the adverse neuromuscular activities of Pregnenolone.Experimental
PrenylaminePrenylamine may increase the neuromuscular blocking activities of Mivacurium.Withdrawn
ProcainamideProcainamide may increase the neuromuscular blocking activities of Mivacurium.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Mivacurium.Experimental
PyridostigminePyridostigmine may decrease the neuromuscular blocking activities of Mivacurium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Mivacurium.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Mivacurium.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Mivacurium.Approved
RimexoloneMivacurium may increase the adverse neuromuscular activities of Rimexolone.Approved
RisedronateRisedronate may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
RivastigmineRivastigmine may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
SevofluraneSevoflurane may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
SisomicinSisomicin may increase the respiratory depressant activities of Mivacurium.Investigational
SP1049CSP1049C may increase the respiratory depressant activities of Mivacurium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Mivacurium.Approved, Vet Approved
SpironolactoneSpironolactone may increase the neuromuscular blocking activities of Mivacurium.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Mivacurium.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Mivacurium.Approved
TacrineTacrine may decrease the neuromuscular blocking activities of Mivacurium.Withdrawn
TetracyclineTetracycline may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
TixocortolMivacurium may increase the adverse neuromuscular activities of Tixocortol.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Mivacurium.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuromuscular blocking activities of Mivacurium.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Mivacurium.Approved
TranilastTranilast may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
TriamcinoloneMivacurium may increase the adverse neuromuscular activities of Triamcinolone.Approved, Vet Approved
TrichlorfonTrichlorfon may decrease the neuromuscular blocking activities of Mivacurium.Vet Approved
TubocurarineTubocurarine may decrease the neuromuscular blocking activities of Mivacurium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Mivacurium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Mivacurium.Approved
VerapamilVerapamil may increase the neuromuscular blocking activities of Mivacurium.Approved
VinpocetineVinpocetine may increase the neuromuscular blocking activities of Mivacurium.Investigational
XylometazolineXylometazoline may increase the neuromuscular blocking activities of Mivacurium.Approved
ZiconotideZiconotide may increase the neuromuscular blocking activities of Mivacurium.Approved
ZorubicinZorubicin may increase the respiratory depressant activities of Mivacurium.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Maurizio Francesco Velati, Andrea Busca, Cristina Manfrotto, Marco Nicolini, Claudio Gianluca Pozzoli, “Process for the preparation of mivacurium chloride.” U.S. Patent US20070293534, issued December 20, 2007.

US20070293534
General ReferencesNot Available
External Links
ATC CodesM03AC10
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelDownload (1.5 MB)
MSDSDownload (25.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9832
Blood Brain Barrier+0.9465
Caco-2 permeable+0.629
P-glycoprotein substrateSubstrate0.8476
P-glycoprotein inhibitor INon-inhibitor0.5119
P-glycoprotein inhibitor IIInhibitor0.7645
Renal organic cation transporterNon-inhibitor0.5515
CYP450 2C9 substrateNon-substrate0.8376
CYP450 2D6 substrateNon-substrate0.7529
CYP450 3A4 substrateSubstrate0.6975
CYP450 1A2 substrateNon-inhibitor0.8986
CYP450 2C9 inhibitorNon-inhibitor0.9583
CYP450 2D6 inhibitorNon-inhibitor0.8914
CYP450 2C19 inhibitorNon-inhibitor0.9348
CYP450 3A4 inhibitorNon-inhibitor0.8426
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.919
Ames testNon AMES toxic0.7046
CarcinogenicityNon-carcinogens0.9137
BiodegradationNot ready biodegradable0.876
Rat acute toxicity2.6607 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8134
hERG inhibition (predictor II)Non-inhibitor0.6401
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
LiquidIntravenous2 mg
SolutionIntravenous2 mg/mL
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility3.26e-05 mg/mLALOGPS
logP3.8ALOGPS
logP-0.76ChemAxon
logS-7.5ALOGPS
pKa (Strongest Acidic)18.59ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area144.9 Å2ChemAxon
Rotatable Bond Count30ChemAxon
Refractivity308.74 m3·mol-1ChemAxon
Polarizability116.68 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoquinolines and derivatives
Sub ClassBenzylisoquinolines
Direct ParentBenzylisoquinolines
Alternative Parents
Substituents
  • Benzylisoquinoline
  • Tetrahydroisoquinoline
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Fatty acid ester
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Quaternary ammonium salt
  • Carboxylic acid ester
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Ihmsen H, Schmidt J, Schwilden H, Schmitt HJ, Muenster T: Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy. Anesthesiology. 2009 May;110(5):1016-9. doi: 10.1097/ALN.0b013e31819daf31. [PubMed:19352159 ]
  4. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616 ]
  5. Jonsson M, Gurley D, Dabrowski M, Larsson O, Johnson EC, Eriksson LI: Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade. Anesthesiology. 2006 Sep;105(3):521-33. [PubMed:16931985 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonistpartial agonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Habre W, Adamicza A, Lele E, Novak T, Sly PD, Petak F: The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906. doi: 10.1213/ane.0b013e318186587c. [PubMed:19020136 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Kao YJ, Le ND: The reversal of profound mivacurium-induced neuromuscular blockade. Can J Anaesth. 1996 Nov;43(11):1128-33. [PubMed:8922768 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23